What the future holds for women after menopause: where we have been, where we are, and where we want to go

References

• http://www.census.gov/population
   Google Scholar
• www.pharmamedtechbiocom/publications/the-pink-sheet/52/019
   Google Scholar
• Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47–63
   PubMed Web of Science ®Google Scholar
• Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991;151:75–8
   PubMed Web of Science ®Google Scholar
• Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016–37
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047–59
   PubMed Web of Science ®Google Scholar
• Anderson GL, Chlebowski RT, Argaki AK, et al. Conjugated equine estrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomized placebo-controlled trial. Lancet Oncol 2012;13:476–86
   PubMed Web of Science ®Google Scholar
• Ross RK, Pike MC, Henderson BE, Mack TM, Lobo RA. Stroke prevention and oestrogen replacement therapy. Lancet 1989;I:505
   Google Scholar
• Mendelsohn ME, Karas RH. Mechanisms of disease: The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801–11
   PubMed Web of Science ®Google Scholar
• Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science 2005;308:1583–7
   PubMed Web of Science ®Google Scholar
• Lobo RA, Whitehead M. Too much of a good thing? Use of progestogens in the menopause: An international consensus statement. Fertil Steril 1989;51:229–31
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605–13
   PubMed Web of Science ®Google Scholar
• Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522–9
   PubMed Web of Science ®Google Scholar
• Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• Burger HG, MacLennan AH, Huang K-E, Castelo-Branco C. Evidence-based assessment of the impact of the WHI on women's health. Climacteric 2012;15:281–7
   PubMed Web of Science ®Google Scholar
• NHLBI stops trial of estrogen plus progestin due to increased breast cancer risk and lack of overall benefit. South Med J 2002;95:795–7
   PubMed Web of Science ®Google Scholar
• Ettinger B, Wang SM, Leslie RS, et al. Evolution of postmenopausal hormone therapy between 2002 and 2009. Menopause 2012;19:610–15
   PubMed Web of Science ®Google Scholar
• Sprague BL, Trentham-Dietz A, Cronin KA. A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999–2010. Obstet Gynecol 2012;120:595–603
   PubMed Web of Science ®Google Scholar
• Gompel A, Plu-Bureau G. Is the decrease in breast cancer incidence related to a decrease in postmenopausal hormone therapy? Ann NY Acad Sci 2010;1205:268–76
   PubMed Web of Science ®Google Scholar
• Stevenson JC, Hodis HN, Pickar JH, Lobo RA. Coronary heart disease and menopause management: the swinging pendulum of HRT. Atherosclerosis 2009;207:336–40
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Hendrix SL, Langer RD, et al. WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 2003;289:3243–53
   PubMed Web of Science ®Google Scholar
• Anderson GL, Chlebowski RT, Rossouw JE. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen and progestin. Maturitas 2006;55:107–15
   Google Scholar
• Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295:1647–57
   PubMed Web of Science ®Google Scholar
• Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006;166:357–65
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and cardiovascular disease by age and years since menopause. JAMA 2007;297:1465–77
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Walsh JM, Greyber E, Salpeter EE. Brief report: coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J Gen Intern Med 2006;21:363–6
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Cheng J, Thabane L, Buckley NS, Salpeter EE. Bayesian meta-analysis of hormone therapy and mortality in younger post-menopausal women. Am J Med 2009;122:1016–22
   PubMed Web of Science ®Google Scholar
• LaCroix AZ, Chlebowski RT, Manson JE, et al.; WHI Investigators. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011;305:1305–14
   PubMed Web of Science ®Google Scholar
• Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 2013;310:1353–68
   PubMed Web of Science ®Google Scholar
• de Villiers TJ, Pines A, Panay N, et al.; International Menopause Society. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 2013;16:316–37
   PubMed Web of Science ®Google Scholar
• Islam S, Liu Q, Chines A, Hetzer E. Trend in incidence of osteoporosis-related fractures among 40- to 69-year-old women: analysis of a large insurance claims database, 2000–2005. Menopause 2009;16:77–83
   PubMed Web of Science ®Google Scholar
• Karim R, Dell RM, Greene DF, Mack WJ, Gallagher JC, Hodis HN. Hip fracture in postmenopausal women after cessation of hormone therapy: results from a prospective study in a large health management organization. Menopause 2011;18:1172–7
   PubMed Web of Science ®Google Scholar
• Sarrel PM, Njike V, Vinante V, Katz DL. The mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women age 50 to 59. Am J Pub Health 2013;103:1583–8
   PubMed Web of Science ®Google Scholar
• Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: A randomized trial. Ann Intern Med 2014 July 29. Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Hodis H. Update on ELITE. Presented at the 14th World Congress on Menopause, Cancun, Mexico, May 1–4, 2014
   Google Scholar
• Schierbeck IL, Renmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomized trial. BMJ 2012; 345:e6409
   PubMed Web of Science ®Google Scholar
• Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010;95(7 Suppl 1):s1–66
   Google Scholar
• US National Safety Council: www.nsc.org
   Google Scholar
• Bolland MJ, Barber PA, Doughty RN, et al. Vascular events in healthy older women receiving calcium supplementation: randomized controlled trial. BMJ 2008;336:262–6
   PubMed Web of Science ®Google Scholar
• Santen RJ, Kronenberg HM, Melmed S, et al. Endocrine responsive cancer. In Williams Textbook of Endocrinology, 11th edn. Philadelphia: Saunders Elsevier, 2008:1764
   Google Scholar
• Robson M, Offit K. Clinical practice. Management of an inherited predisposition to breast cancer. N Engl J Med 2007; 357:154–62
   PubMed Web of Science ®Google Scholar
• Marie-Genica Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk. Polymorphisms in genes of the steroid receptor superfamily modify postmenopausal breast cancer risk associated with menopausal hormone therapy. Int J Cancer 2010;126:2935–46
   PubMed Web of Science ®Google Scholar
• Hein R, Flesch-Janys D, Dahmen N, et al. A genome-wide association study to identify genetic susceptibility loci that modify ductal and lobular postmenopausal breast cancer risk associated with menopausal hormone therapy use: a two-stage design with replication. Breast Cancer Res 2013;138:529–42
   Web of Science ®Google Scholar
• Ryan J, Canonico M, Carcaillon L, et al. Hormone treatment, estrogen receptor polymorphisms and mortality: a prospective cohort study. PLoS One 2012;7:e34112
   Google Scholar
• Bouligand J, Cabaret O, Canonico M, et al. Effect of NFE2L2 genetic polymorphism on the association between oral estrogen therapy and the risk of venous thromboembolism in postmenopausal women. Clin Pharmacol Ther 2011;89:60–4
   PubMed Web of Science ®Google Scholar
• Canonico M, Bouaziz E, Carcaillon L, et al. Synergism between oral estrogen therapy and cytochrome P450 3A5*1 allele on the risk of venous thromboembolism among postmenopausal women. J Clin Endocrinol Metab 2008;93:3082–7
   PubMed Web of Science ®Google Scholar
• Ryan J, Ancelin ML. Polymorphisms of estrogen receptors and risk of depression: therapeutic implications. Drugs 2012; 72:1725–38
   PubMed Web of Science ®Google Scholar
• Yip VL, Pirmohamed M. Expanding role of pharmacogenomics in the management of cardiovascular disorders. Am J Cardiovasc Drugs 2013;13:151–62
   PubMed Web of Science ®Google Scholar
• Herrington DM, Howard TD, Hawkins GA, et al. Estrogen- receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med 2002;346:967–74
   PubMed Web of Science ®Google Scholar
• Lobo RA, Davis SR, De Villiers TJ, et al. Prevention of diseases after menopause. Climacteric 2014 June 27. Epub ahead of print
   Web of Science ®Google Scholar
• Komm BS, Mirkin S, Jenkins SN. Development of conjugated estrogens/bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone loss. Steroids 2014 June 14. Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Bagger YZ, Tanko LB, Alexandersen P, et al. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 2004;34:728–35
   PubMed Web of Science ®Google Scholar
• Bagger YZ, Tanko LB, Alexandersen P, et al. Early postmenopausal hormone therapy may prevent cognitive impairment later in life. Menopause 2005;12:12–17
   PubMed Web of Science ®Google Scholar